Protocols

Peregrine slashes R&D in a reorg that claims 60 jobs; Zai Labs in hunt for $150M IPO – report

Samantha Du

⇨ A year after its lead cancer drug flopped in Phase III, Peregrine Pharmaceuticals $PPHM is bringing out the ax and slashing its staff by 60 employees. The Tustin, CA-based biotech says it reduced its R&D group by half, down to 11 workers, while its contract manufacturing division Avid Bioservices was also cut. This is all a result of a strategic review underway to survey options for its R&D assets.

⇨ Bloomberg is reporting that China’s Zai Labs is lining up a $150 million IPO. The Shanghai-based company, led by CEO Samantha Du, is looking for a market valuation of about a billion dollars, a fresh sign of the boom times for biotech in the Asian market.

⇨ Perrigo has sold its API business to SK Capital for $110 million. The buyout comes with a supply agreement for marketed as well as experimental products.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 28,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

BIO 2018

Private Equity Senior Associate
OrbiMed Advisors New York, NY
Business Development Manager
Novotech Boston, MA
Director, Cell MS&T
Adaptimmune Philadelphia, PA

Visit Endpoints Careers ->